Title: AMEND S e n ate Bill No. 428 House Bill No. 37*
Official Title: AMEND S e n ate Bill No. 428 House Bill No. 37*
Number of Sections: 3
Source: versions - Amendment SA0297
Media Type: application/pdf
Strikethrough Detection: 2 sections found

================================================================================

Section 1:
Senate Finance, Ways, and Means 1
Amendment No. 1 to SB0428
Watson
Signature of Sponsor
by deleting all language after the enacting clause and substituting:

Section 2:
SECTION 1. Tennessee Code Annotated, Title 56, Chapter 7, is amended by adding
the following new part:
56-7-3801.
As used in this part:
(1) "Group insurance plan" means a group insurance plan that covers
state employees approved pursuant to title 8, chapter 27;
(2) "Healthcare prescriber" means a prescriber as defined in ยง 53-10-
203;
(3) "Insurer" means an insurer that offers a group insurance plan; and
(4) "Non-opioid treatment" means a drug or biological product that is
indicated to produce analgesia without acting on the body's opioid receptors.
56-7-3802.
(a) Except as otherwise provided in this section, an insurer, for purposes of
offering a group insurance plan, may adopt or amend a state preferred drug list (PDL).
(b)
(1) In establishing and maintaining the PDL, the insurer shall ensure that
a non-opioid drug approved by the United States food and drug administration for
the treatment or management of pain is not disadvantaged or discouraged with
respect to coverage relative to an opioid or narcotic drug for the treatment or
management of pain on the PDL.
SA0297
004531
- 1 -
(2) Subdivision (b)(1) does not prohibit an opioid medication from being
preferred over other opioid medications, or a non-opioid medication from being
preferred over other non-opioid medications.
(c) This section applies to a non-opioid drug after it has been approved by the
United States food and drug administration for a period of nine months or longer for the
treatment or management of pain, regardless of whether the drug has been reviewed by
the insurer for inclusion on the PDL. This section also applies to drugs being provided
under a contract between the insurer and a pharmacy benefits manager for purposes of
a group insurance plan.

Section 3:
SECTION 2. This act takes effect January 1, 2026, the public welfare requiring it.
- 2 - 004531
[DELETED:  a HS5A((((5(( (]
[DELETED:  -0((S]


================================================================================

Raw Text:
Senate Finance, Ways, and Means 1
Amendment No. 1 to SB0428
Watson
Signature of Sponsor
AMEND S e n ate Bill No. 428 House Bill No. 37*
by deleting all language after the enacting clause and substituting:
SECTION 1. Tennessee Code Annotated, Title 56, Chapter 7, is amended by adding
the following new part:
56-7-3801.
As used in this part:
(1) "Group insurance plan" means a group insurance plan that covers
state employees approved pursuant to title 8, chapter 27;
(2) "Healthcare prescriber" means a prescriber as defined in ยง 53-10-
203;
(3) "Insurer" means an insurer that offers a group insurance plan; and
(4) "Non-opioid treatment" means a drug or biological product that is
indicated to produce analgesia without acting on the body's opioid receptors.
56-7-3802.
(a) Except as otherwise provided in this section, an insurer, for purposes of
offering a group insurance plan, may adopt or amend a state preferred drug list (PDL).
(b)
(1) In establishing and maintaining the PDL, the insurer shall ensure that
a non-opioid drug approved by the United States food and drug administration for
the treatment or management of pain is not disadvantaged or discouraged with
respect to coverage relative to an opioid or narcotic drug for the treatment or
management of pain on the PDL.
SA0297
004531
- 1 -

(2) Subdivision (b)(1) does not prohibit an opioid medication from being
preferred over other opioid medications, or a non-opioid medication from being
preferred over other non-opioid medications.
(c) This section applies to a non-opioid drug after it has been approved by the
United States food and drug administration for a period of nine months or longer for the
treatment or management of pain, regardless of whether the drug has been reviewed by
the insurer for inclusion on the PDL. This section also applies to drugs being provided
under a contract between the insurer and a pharmacy benefits manager for purposes of
a group insurance plan.
SECTION 2. This act takes effect January 1, 2026, the public welfare requiring it.
- 2 - 004531

[DELETED:  a HS5A((((5(( (]
[DELETED:  -0((S]